Our meta-analysis suggested that the CTLA-4 49A/G polymorphism is associated with a decreased NHL, multiple myeloma, and leukemia risk, while the CTLA-4 319C/T polymorphism is significantly associated with a decreased CLL risk. Here, CTLA4 is linked to non-Hodgkin lymphoma.